Deutsche Bank Reiterates Neutral Rating for Merck KGaA (MRK)
Merck KGaA (FRA:MRK)‘s stock had its “neutral” rating reaffirmed by equities research analysts at Deutsche Bank in a report released on Friday.
Several other brokerages have also issued reports on MRK. Oddo Bhf set a €125.00 ($154.32) target price on Merck KGaA and gave the company a “buy” rating in a research report on Friday, November 10th. JPMorgan Chase & Co. set a €95.00 ($117.28) target price on Merck KGaA and gave the company a “neutral” rating in a research report on Friday, December 29th. DZ Bank reaffirmed a “buy” rating on shares of Merck KGaA in a research report on Monday, February 12th. UBS Group set a €120.00 ($148.15) target price on Merck KGaA and gave the company a “buy” rating in a research report on Friday, February 16th. Finally, Nord/LB reaffirmed a “neutral” rating on shares of Merck KGaA in a research report on Tuesday, January 2nd. Twelve analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average target price of €102.86 ($126.99).
Merck KGaA (FRA MRK) opened at €78.48 ($96.89) on Friday. The company has a market capitalization of $10,080.00 and a price-to-earnings ratio of 13.12. Merck KGaA has a 1 year low of €76.60 ($94.57) and a 1 year high of €115.00 ($141.98).
Merck KGaA Company Profile
MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.